Compare HIO & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIO | AURA |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.2M | 377.2M |
| IPO Year | N/A | 2021 |
| Metric | HIO | AURA |
|---|---|---|
| Price | $3.64 | $6.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 398.9K | 251.4K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.36 | $4.73 |
| 52 Week High | $4.05 | $7.48 |
| Indicator | HIO | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 62.04 |
| Support Level | N/A | $5.83 |
| Resistance Level | $3.89 | $6.73 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 59.11 | 73.03 |
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.